17th Jul 2009 10:39
|
|
17 July 2009 |
MINSTER PHARMACEUTICALS PLC
("Minster" or "the Company")
Director's share purchase
Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, was notified on 16 July 2009 that Karl Keegan, Chief Financial Officer, purchased 151,900 ordinary shares of 5 pence each in the Company ("Ordinary Shares") on 16 July 2009 at a price of 6.5 pence per Ordinary Share.
Following the transaction, Mr Keegan's beneficial interest in the Company is 151,900 Ordinary Shares, representing approximately 0.26 per cent of the issued share capital in the Company.
For further information:
|
Minster Pharmaceuticals plc |
|
|
Karl Keegan, Chief Financial Officer |
Tel: +44 (0) 20 7936 9921 |
|
Jeremy Gorman, Company Secretary |
Tel: +44 (0) 20 7935 0027 |
|
|
|
|
Buchanan Communications |
Tel: +44 (0) 20 7466 5000 |
|
Mark Court / Rebecca Skye Dietrich / Catherine Breen |
|
|
|
|
|
Nomura Code Securities Limited |
Tel: +44 (0) 20 7776 1200 |
|
Chris Collins / Richard Potts |
|
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com.
Related Shares:
MPM.L